Duloxetine As an Analgesic in Patients Without Central Sensitivity After Same Sitting Bilateral Total Knee Arthroplasty
CompletedPhase 4NCT06837012
View the official record on ClinicalTrials.gov Recruiting status changes often. Contact the study team listed on ClinicalTrials.gov, and talk to your doctor before joining a study.
This study has no listed site in Canada in this snapshot. It is included as part of the worldwide chronic pain corpus.
Brief summary (from the registry)
Analgesic effect of 20mg Duloxetine was evaluated at regular short term intervals in patients without central sensitivity and undergoing bilateral single sitting total knee arthroplasty for tricompartmental osteoarthritis using standardised patient related outcome measures like the visual analogue score.
Study details
- Official title
- Duloxetine As an Analgesic in Patients Without Central Sensitivity Undergoing Single-sitting, Bilateral Total Knee Arthroplasty: a Prospective, Double-blinded, Randomised, Placebo-controlled Trial
- Conditions
- Osteoarthritis of Knee
- Central Sensitization
- Central Sensitisation
- Interventions
- Drug: Duloxetine - low dose
- Drug: Placebo
- Sponsor
- Orthopaedic Arthroscopy Knee and Shoulder Clinic
- Collaborators
- The Grant Medical College & Sir J.J. Group of Hospitals
- Start date
- 2021-01-01
- Primary completion
- 2022-07-31
- Sex
- All
- Healthy volunteers
- true
- Results posted
- No results posted in this snapshot
- Countries
- India
- Total sites listed
- 1
Eligibility criteria
Show eligibility criteria (verbatim from the registry)
Inclusion Criteria: * Bilateral tricompartmental knee osteoarthritis * Underwent primary, bilateral TKA in single-sitting Exclusion Criteria: * American Society of Anesthesiologists physical status IV * Hamilton Depression Scale (HAMD) and/or Hamilton Anxiety Scale (HAMA) scores \> 7 * known intolerance or allergy to any of the study drugs, alcohol, tobacco, narcotic, or opioid dependence * patients on anticoagulants * known hepatic/renal dysfunction * serious cardiac/cerebrovascular comorbidities * HbA1c≥7 * patients who were already on duloxetine or other SNRIs, monoamine oxidase inhibitors, tricyclic antidepressants, triptans, lithium, other antiepileptics, or buspirone.
Source: ClinicalTrials.gov (US National Library of Medicine), snapshot October 2026. Check the registry for current recruiting status. Record: https://clinicaltrials.gov/study/NCT06837012